Filana Therapeutics Inc. (FLNA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Filana Therapeutics Inc. (NASDAQ: FLNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.66 (+1.12% 1D, market cap $31.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FLNA ranks #421 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FLNA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AARD (Aardvark Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $31.5M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, FLNA leads on earnings multiple (N/A) while IBO leads on capital efficiency (-27.5% ROIC).
Per FLNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001069530), Filana Therapeutics Inc. generated $0 in revenue, -$91.0M in net income, and -$32.8M in free cash flow against $118.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While FLNA currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.79) and Max Pain ($0.69) forces dealer call-delta covering toward $3.62.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Filana Therapeutics Inc. (FLNA) advanced +1.12% to $0.66, trading at 2% of its 52-week range ($0.6 – $3.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Findings provide new insight into simufilam’s effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the ATF4-associated
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex
https://www.sec.gov/ix?doc=/Archives/edgar/data/1069530/000143774926032971/sava20261019_8k.htm
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on FLNA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for FLNA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Filana Therapeutics Inc. (FLNA) ranks #421 by composite RQD confidence (47/100, grade D) and #797 by equity capitalization ($31.8M). Within this direct 5-issuer industry benchmark cohort, FLNA leads on earnings valuation at N/A trailing P/E, while IBO leads on capital efficiency and profitability with -27.5% ROIC and -30.0% gross margin. FLNA currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FLNA
ACTIVE
Filana Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +1.12% | $31.8M | Benchmark Subject |
| AARD Aardvark Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -4.64% | $31.5M | /aard-vs-flna → |
| IXHL Incannex Healthcare Inc. | D- | 39/100 | — | — | -35.0% | -4.80% | $32.4M | /ixhl-vs-flna → |
| IBO Impact BioMedical Inc. | E | 34/100 | — | -30.0% | -27.5% | -3.00% | $33.1M | /ibo-vs-flna → |
| ACET Adicet Bio Inc. | D- | 36/100 | — | — | -35.0% | -6.04% | $33.5M | /acet-vs-flna → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Filana Therapeutics Inc. (FLNA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$91.0M, operating cash flow of -$32.3M, and free cash flow of -$32.8M (+71.9% YoY). On the balance sheet, FLNA closed FY2025 with $118.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$91.0M | -$32.3M | -$32.8M | $118.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$24.3M | -$116.9M | -$117.0M | $157.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$97.2M | -$82.0M | -$82.0M | — | — |
As of 2026-11-01, Filana Therapeutics Inc. (NASDAQ: FLNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.66 (+1.12% 1D, market cap $31.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FLNA ranks #421 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FLNA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AARD (Aardvark Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $31.5M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, FLNA leads on earnings multiple (N/A) while IBO leads on capital efficiency (-27.5% ROIC).
Per FLNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001069530), Filana Therapeutics Inc. generated $0 in revenue, -$91.0M in net income, and -$32.8M in free cash flow against $118.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
FLNA last traded at $0.66 (+1.12% on volume of 265,174 shares), positioning the stock -16.46% below its 50-day simple moving average ($0.79) and -51.47% below its 200-day simple moving average ($1.36). Across its 52-week range of $0.60 to $3.45, FLNA sits at the 2.1% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.74).
Why FLNA Stock advanced +1.12% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.